Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP)

Pediatric Blood and Cancer

Volumn 62, Issue 2, 2015, Pages 208-213

  Bussel, James B ^a   Hsieh, Loan ^b   Buchanan, George R ^c   Stine, Kimo ^d   Kalpatthi, Ram ^e   Gnarra, David J ^f   Ho, Richard H ^g   Nie, Kun ^h   Eisen, Melissa ^h  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ARKANSAS CHILDREN S HOSPITAL   (United States)

^e CHILDREN S MERCY HOSPITAL   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^h AMGEN INC   (United States)

Author keywords

Autoimmunity; Bleeding; Platelets; Thrombopoietin

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; AZATHIOPRINE; DANAZOL; DAPSONE; DEXAMETHASONE; HYDROCORTISONE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RHESUS D ANTIBODY; ROMIPLOSTIM; VINCRISTINE; FC RECEPTOR; HYBRID PROTEIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ADOLESCENT; ALTERNATIVE MEDICINE; ARTHRALGIA; ARTICLE; ASTHMA; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD TRANSFUSION REACTION; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTUSION; COUGHING; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FEVER; GINGIVA BLEEDING; HEMANGIOMA; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLUENZA; LONG TERM CARE; LYMPHADENITIS; MALE; NAUSEA; NOSE OBSTRUCTION; OPEN STUDY; ORAL BLEEDING; OROPHARYNX PAIN; PAIN; PETECHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RHINOPHARYNGITIS; RHINORRHEA; SEPSIS; SPLENECTOMY; STREPTOCOCCAL PHARYNGITIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGONISTS; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFECTS; INFANT; LONGITUDINAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOCYTE; TREATMENT OUTCOME;

ADOLESCENT; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84927556174     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25136     Document Type: Article

References (26)

1. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168-186.
2. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J; ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76:205-213.
3. Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): Study of 40 cases. Blood 2009; 114:4777-4783.
4. Imbach P. Refractory idiopathic immune thrombocytopenic purpura in children: Current and future treatment options. Paediatric Drugs 2003; 5:795-801.
5. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo Hr, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus Mr, Guo DM, Nichol JL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008; 371:395-403.
6. Kuter DJ, Rummel M, Boccia R, Macik BJ, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889-1899.
7. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672-1681.
8. George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, Redner RL, Rice L, Schipperus MR. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: Results from two randomized, placebo-controlled trials. Br J Haematol 2009; 144:409-415.
9. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, Nichol JL. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010; 8:1372-1382.
10. Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia (ITP): A pooled analysis of 13 clinical trials. Eur J Haematol 2013; 423-436.
11. Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011; 118:28-36.
12. Mokhtar GM, Tantawy AA, El Sherif NH. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. Platelets 2012; 23:264-273.
13. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113:2161-2171.
14. Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): Final report from an open-label extension study. Br J Haemat 2013; 161:411-423.
15. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichten AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3-40.
16. Flores A, Buchanan GR. Bleeding severity as an important outcome in childhood immune thrombocytopenia. Pediatr Blood Cancer 2013; 60:S8-11.
17. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: The choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012; 120:960-969.
18. Cooper N. A review of the management of childhood immune thrombocytopenia: How can we provide an evidence-based approach? Br J Haematol 2014.
19. Patel VL, Mahevas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL, Bierling P, Lesser M, Cooper N, Bussel JB. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012; 119:5989-5995.
20. Cooper N, Bussel JB. The long-term impact of rituximab for childhood immune thrombocytopenia. Curr Rheumatol Rep 2010; 12:94-100.
21. Martindale: The Complete Drug Reference: Danazol Drug Monograph 2014 [cited 2014 April 1, 2014]. Available from: http://www.medicinescomplete.com/mc/martindale/current/9035-v.htm?q=danazol&t=search&ss=text&p=1#m9035-a1-d.
22. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study. Blood 2013; 121:537-545.
23. Klaassen RJ, Mathias SD, Buchanan G, Bussel J, Deuson R, Young NL, Collier A, Bomgaars L, Blanchette V. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer 2012; 58:395-398.
24. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009; 114:3748-3756.
25. GlaxoSmithKline. PROMACTA® (eltrombopag) prescribing information 2012 [updated November 2012; cited 2013 July 26]. Available from: http://us.gsk.com/products/assets/us_promacta.pdf.
26. Khellaf M, Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, Fain O, Audia S, Abgrall JF, Michot JM, Dauriac C, Lefort S, Gyan E, Niault M, Durand JM, Languille L, Boutboul D, Bierling P, Michel M, Godeau B. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 2013; 98:881-887.